Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             225 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A comparative study to evaluate the safety and immunogenicity of two lots of Haemophilus influenzae type-B conjugate vaccine manufactured at different scales Hirve, Siddhivinayak
2011
29 Supplement 3 p. 5363-5367
5 p.
artikel
2 A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings—A randomised blind study Gildea, Sarah
2011
29 Supplement 3 p. 9214-9223
10 p.
artikel
3 Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice Schneider-Ohrum, Kirsten
2011
29 Supplement 3 p. 9081-9092
12 p.
artikel
4 A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection Lima, Danielle Malta
2011
29 Supplement 3 p. 831-838
8 p.
artikel
5 Adolescents’ awareness of HPV infections and attitudes towards HPV vaccination 3 years following the introduction of the HPV vaccine in Hungary Marek, Erika
2011
29 Supplement 3 p. 8591-8598
8 p.
artikel
6 Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone® in rhesus macaques Carroll, Timothy D.
2011
29 Supplement 3 p. 931-940
10 p.
artikel
7 Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals Bernatchez, Chantale
2011
29 Supplement 3 p. 3021-3030
10 p.
artikel
8 An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers Madhun, Abdullah S.
2010
29 Supplement 3 p. 266-273
8 p.
artikel
9 A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness Langley, J.M.
2011
29 Supplement 3 p. 1921-1928
8 p.
artikel
10 Antibody persistence at 18–20months of age and safety and immunogenicity of a booster dose of a combined DTaP–IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China Li, Rong Cheng
2011
29 Supplement 3 p. 9337-9344
8 p.
artikel
11 Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation Cranage, Martin P.
2011
29 Supplement 3 p. 1421-1430
10 p.
artikel
12 A pandemic influenza vaccine in India: From strain to sale within 12 months Dhere, Rajeev
2011
29 Supplement 3 p. A16-A21
nvt p.
artikel
13 A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients Staff, Caroline
2011
29 Supplement 3 p. 6817-6822
6 p.
artikel
14 A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects Keefer, Michael C.
2011
29 Supplement 3 p. 1948-1958
11 p.
artikel
15 A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV Somogyi, Eszter
2011
29 Supplement 3 p. 744-753
10 p.
artikel
16 A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years Tennis, Patricia
2011
29 Supplement 3 p. 4947-4952
6 p.
artikel
17 A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older Forrest, Bruce D.
2011
29 Supplement 3 p. 3633-3639
7 p.
artikel
18 A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants Bernstein, David I.
2011
29 Supplement 3 p. 7042-7048
7 p.
artikel
19 A single point mutation in framework region 3 of heavy chain affects viral neutralization dynamics of single-chain Fv against bovine herpes virus type 1 Koti, Madhuri
2011
29 Supplement 3 p. 7905-7912
8 p.
artikel
20 Assessing the potency of oral polio vaccine kept outside of the cold chain during a national immunization campaign in Chad Zipursky, Simona
2011
29 Supplement 3 p. 5652-5656
5 p.
artikel
21 A stable plasmid system for heterologous antigen expression in attenuated Vibrio anguillarum Xiao, Yan
2011
29 Supplement 3 p. 6986-6993
8 p.
artikel
22 A systematic review of intradermal influenza vaccines Young, Flora
2011
29 Supplement 3 p. 8788-8801
14 p.
artikel
23 Atopy history and the genomics of wheezing after influenza vaccination in children 6–59 months of age Miller, E. Kathryn
2011
29 Supplement 3 p. 3431-3437
7 p.
artikel
24 Attenuation of bovine herpesvirus type 1 by deletion of its glycoprotein G and tk genes and protection against virulent viral challenge Zhang, Minmin
2011
29 Supplement 3 p. 8943-8950
8 p.
artikel
25 Barriers to implementation of the new targeted BCG vaccination in France: A cross sectional study Rossignol, L.
2011
29 Supplement 3 p. 5232-5237
6 p.
artikel
26 B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax Merozoite Surface Protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon Lima-Junior, J.C.
2011
29 Supplement 3 p. 1801-1811
11 p.
artikel
27 BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity Keyser, Andrew
2011
29 Supplement 3 p. 9308-9315
8 p.
artikel
28 Bioprocess optimization for cell culture based influenza vaccine production Aggarwal, Kunal
2011
29 Supplement 3 p. 3320-3328
9 p.
artikel
29 Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/Th17 promoting mucosal adjuvant Ebensen, Thomas
2011
29 Supplement 3 p. 5210-5220
11 p.
artikel
30 Bone marrow vaccination: A novel approach to enhance antigen specific antitumor immunity Fresnay, Stephanie
2011
29 Supplement 3 p. 8599-8605
7 p.
artikel
31 Bovine respiratory syncytial virus ISCOMs—Immunity, protection and safety in young conventional calves Hägglund, Sara
2011
29 Supplement 3 p. 8719-8730
12 p.
artikel
32 Cancer vaccines and carbohydrate epitopes Heimburg-Molinaro, Jamie
2011
29 Supplement 3 p. 8802-8826
25 p.
artikel
33 Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines Westdijk, Janny
2011
29 Supplement 3 p. 3390-3397
8 p.
artikel
34 Chronological study of cytokine transcription in the spleen and lung of chickens after vaccination with serotype 1 Marek's disease vaccines Gimeno, Isabel M.
2011
29 Supplement 3 p. 1583-1594
12 p.
artikel
35 Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides Denoël, Philippe
2011
29 Supplement 3 p. 6451-6453
3 p.
artikel
36 Comparing live attenuated and inactivated hepatitis A vaccines: An immunogenicity study after one single dose Zheng, Hui
2011
29 Supplement 3 p. 9098-9103
6 p.
artikel
37 Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: Systematic review and meta-analysis Scott, Pippa
2011
29 Supplement 3 p. 9711-9721
11 p.
artikel
38 Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen Vu, David M.
2011
29 Supplement 3 p. 1968-1973
6 p.
artikel
39 Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titers Van Gessel, Yvonne
2011
29 Supplement 3 p. 5925-5931
7 p.
artikel
40 Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: Comparing estimates for 7-valent, 10-valent, and 13-valent vaccines Tyo, Karen Richards
2011
29 Supplement 3 p. 6686-6694
9 p.
artikel
41 Current trend of pneumococcal serotypes distribution and antibiotic susceptibility pattern in Malaysian hospitals Rohani, Md Yasin
2011
29 Supplement 3 p. 5688-5693
6 p.
artikel
42 Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine Yen, Catherine
2011
29 Supplement 3 p. 4151-4155
5 p.
artikel
43 Determination of antigenic properties of vaccine derived poliovirus strains Pliaka, Vaia
2010
29 Supplement 3 p. 26-33
8 p.
artikel
44 Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: Vesiculovirus) Jadi, R.S.
2011
29 Supplement 3 p. 4613-4617
5 p.
artikel
45 Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2 Posavad, Christine M.
2011
29 Supplement 3 p. 7058-7066
9 p.
artikel
46 Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever Osorio, Jorge E.
2011
29 Supplement 3 p. 7251-7260
10 p.
artikel
47 Difficulties in the prevention of cervical cancer: Adults’ attitudes towards HPV vaccination 3 years after introducing the vaccine in Hungary Marek, Erika
2011
29 Supplement 3 p. 5122-5129
8 p.
artikel
48 Diphtheria–tetanus–pertussis vaccine administered simultaneously with measles vaccine is associated with increased morbidity and poor growth in girls. A randomised trial from Guinea-Bissau Agergaard, J.
2011
29 Supplement 3 p. 487-500
14 p.
artikel
49 Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine Somech, Ido
2011
29 Supplement 3 p. 4202-4209
8 p.
artikel
50 Distribution of factor H binding protein beyond serogroup B: Variation among five serogroups of invasive Neisseria meningitidis in South Africa Mothibeli, Kedibone M.
2011
29 Supplement 3 p. 2187-2192
6 p.
artikel
51 Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates Marsh, Jane W.
2011
29 Supplement 3 p. 6049-6058
10 p.
artikel
52 Do the initial serum level changes of sCD26 have ability to predict successful treatment with IFN-α among naïve chronic hepatitis B patients? Alavi-Moghaddam, Mostafa
2011
29 Supplement 3 p. 9093-9097
5 p.
artikel
53 Early immune responses in Atlantic salmon (Salmo salar L.) after immunization with PLGA nanoparticles loaded with a model antigen and β-glucan Fredriksen, B.N.
2011
29 Supplement 3 p. 8338-8349
12 p.
artikel
54 Economic analysis of the global polio eradication initiative Duintjer Tebbens, Radboud J.
2010
29 Supplement 3 p. 334-343
10 p.
artikel
55 Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy Boccalini, Sara
2011
29 Supplement 3 p. 9521-9528
8 p.
artikel
56 Economic evaluation of infant and adolescent hepatitis B vaccination in the UK Siddiqui, M. Ruby
2011
29 Supplement 3 p. 466-475
10 p.
artikel
57 Editorial Board 2011
29 Supplement 3 p. CO2-
1 p.
artikel
58 Editorial Board 2011
29 Supplement 3 p. CO2-
1 p.
artikel
59 Editorial Board/Aims and Scope 2011
29 Supplement 3 p. CO2-
1 p.
artikel
60 Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand Arnold, Richard
2011
29 Supplement 3 p. 7100-7106
7 p.
artikel
61 Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine Miller, Elizabeth
2011
29 Supplement 3 p. 9127-9131
5 p.
artikel
62 Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7–59 months. A matched case-control study Domínguez, Angela
2011
29 Supplement 3 p. 9020-9025
6 p.
artikel
63 Effect of GonaCon™ vaccine on black-tailed prairie dogs: Immune response and health effects Yoder, Christi A.
2010
29 Supplement 3 p. 233-239
7 p.
artikel
64 Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal Shuaibu, M.N.
2011
29 Supplement 3 p. 3239-3247
9 p.
artikel
65 Effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the immune responses to Newcastle disease vaccine in chickens Zhai, Lijuan
2011
29 Supplement 3 p. 5007-5014
8 p.
artikel
66 Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines Carstens, Myrra G.
2011
29 Supplement 3 p. 4761-4770
10 p.
artikel
67 Efficacy of hepatitis B sero-vaccination in newborns of African HBsAg positive mothers Chakvetadze, Catherine
2011
29 Supplement 3 p. 2846-2849
4 p.
artikel
68 Enhanced immune sera and vaccine: Safe approach to treat scorpion envenoming Lila, Boussag-Abib
2011
29 Supplement 3 p. 8951-8959
9 p.
artikel
69 Evaluation of cell-mediated immune responses to two BCG vaccination regimes in young children in South Korea Lee, Hyejon
2011
29 Supplement 3 p. 6564-6571
8 p.
artikel
70 Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products Parveen, Seema
2011
29 Supplement 3 p. 8012-8023
12 p.
artikel
71 Evaluation of novel fusion proteins derived from extracellular matrix binding domains of LigB as vaccine candidates against leptospirosis in a hamster model Cao, Yongguo
2011
29 Supplement 3 p. 7379-7386
8 p.
artikel
72 Evaluation of recombinant fowlpox virus expressing infectious bronchitis virus S1 gene and chicken interferon-γ gene for immune protection against heterologous strains Shi, Xing-Ming
2011
29 Supplement 3 p. 1576-1582
7 p.
artikel
73 Evaluation of the reliability, validity and practicality of 3 measures of acute pain in infants undergoing immunization injections Taddio, Anna
2011
29 Supplement 3 p. 1390-1394
5 p.
artikel
74 Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: Second report of the BCG-REVAC cluster-randomised trial Barreto, Mauricio L.
2011
29 Supplement 3 p. 4875-4877
3 p.
artikel
75 Expected epidemiological impacts of introducing an HIV vaccine in Thailand: A model-based analysis Schneider, Karen
2011
29 Supplement 3 p. 6086-6091
6 p.
artikel
76 Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline Davis, Matthew M.
2011
29 Supplement 3 p. 9414-9416
3 p.
artikel
77 Financing and systems barriers to seasonal influenza vaccine delivery in community settings Penfold, Robert B.
2011
29 Supplement 3 p. 9632-9639
8 p.
artikel
78 French healthcare workers in geriatric healthcare settings staunchly opposed to influenza vaccination: The VESTA study Gavazzi, Gaëtan
2011
29 Supplement 3 p. 1611-1616
6 p.
artikel
79 Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses Mantel, N.
2011
29 Supplement 3 p. 6629-6635
7 p.
artikel
80 Guillain–Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition Choe, Young June
2011
29 Supplement 3 p. 2066-2070
5 p.
artikel
81 Guillain–Barré Syndrome in India: Population-based validation of the Brighton criteria Mateen, Farrah J.
2011
29 Supplement 3 p. 9697-9701
5 p.
artikel
82 Hepatitis B immunity and vaccination coverage among young adult males in the Air Force in South Brazil Passos, Ana Maria
2011
29 Supplement 3 p. 9284-9288
5 p.
artikel
83 Hepatitis B vaccination coverage among high-risk adults 18–49 years, U.S., 2009 Lu, Peng-jun
2011
29 Supplement 3 p. 7049-7057
9 p.
artikel
84 High burden of tick-borne encephalitis in Slovenia—Challenge for vaccination policy Grgič-Vitek, Marta
2011
29 Supplement 3 p. 5178-5183
6 p.
artikel
85 Highly effective generic adjuvant systems for orphan or poverty-related vaccines Rao, Mangala
2011
29 Supplement 3 p. 873-877
5 p.
artikel
86 H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals Lee, Dong-Hun
2011
29 Supplement 3 p. 4003-4007
5 p.
artikel
87 Hospital initiation of a vaccinal schedule improves the long-term vaccinal coverage of ex-preterm children Denizot, S.
2011
29 Supplement 3 p. 382-386
5 p.
artikel
88 HPV vaccination in France: Uptake, costs and issues for the National Health Insurance Fagot, Jean-Paul
2011
29 Supplement 3 p. 3610-3616
7 p.
artikel
89 Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital Schluterman, Nicholas H.
2011
29 Supplement 3 p. 3767-3772
6 p.
artikel
90 Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14—Lysine modified PspA Santamaria, Raquel
2011
29 Supplement 3 p. 8689-8695
7 p.
artikel
91 Identification and characterization of a cross-neutralization epitope of Enterovirus 71 Liu, Chia-Chyi
2011
29 Supplement 3 p. 4362-4372
11 p.
artikel
92 Identification of a new protective antigen of Bordetella pertussis Alvarez Hayes, Jimena
2011
29 Supplement 3 p. 8731-8739
9 p.
artikel
93 Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins Hendrikx, Lotte H.
2011
29 Supplement 3 p. 1431-1437
7 p.
artikel
94 Immune response of varicella vaccinees to different varicella-zoster virus genotypes Sauerbrei, A.
2011
29 Supplement 3 p. 3873-3877
5 p.
artikel
95 Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime–boost immunisation in non-human primates Capone, Stefania
2010
29 Supplement 3 p. 256-265
10 p.
artikel
96 Immune responses induced by heat killed Saccharomyces cerevisiae: A vaccine against fungal infection Liu, Min
2011
29 Supplement 3 p. 1745-1753
9 p.
artikel
97 Immunization of female BALB/c mice with Neospora cyclophilin and/or NcSRS2 elicits specific antibody response and prevents against challenge infection by Neospora caninum Tuo, Wenbin
2011
29 Supplement 3 p. 2392-2399
8 p.
artikel
98 Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP–IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea Lee, Soo Young
2011
29 Supplement 3 p. 1551-1557
7 p.
artikel
99 Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: A randomized, open-label, phase 3 study Bernstein, Henry H.
2011
29 Supplement 3 p. 2212-2221
10 p.
artikel
100 Immunogenicity and safety of a Haemophilus influenzae B (Hib)–hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants Lee, Andrew W.
2011
29 Supplement 3 p. 7942-7948
7 p.
artikel
101 Immunogenicity and safety of a measles–mumps–rubella–varicella vaccine following a 4-week or a 12-month interval between two doses Rümke, H.C.
2011
29 Supplement 3 p. 3842-3849
8 p.
artikel
102 Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study Rusnak, Janice M.
2011
29 Supplement 3 p. 3222-3229
8 p.
artikel
103 Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China Li, Rong Cheng
2011
29 Supplement 3 p. 1913-1920
8 p.
artikel
104 Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents Garcia-Sicilia, J.
2011
29 Supplement 3 p. 4353-4361
9 p.
artikel
105 Immunogenicity and safety of fully liquid DTaP5-IPV-Hib compared with DTaP3-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: A phase III, single-blind, randomised, controlled, multicentre study Grimprel, Emmanuel
2011
29 Supplement 3 p. 7370-7378
9 p.
artikel
106 Immunogenicity and safety of intradermal influenza vaccine in children Esposito, Susanna
2011
29 Supplement 3 p. 7606-7610
5 p.
artikel
107 Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine Gimenez-Sanchez, Francisco
2011
29 Supplement 3 p. 6042-6048
7 p.
artikel
108 Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys Koeberling, Oliver
2011
29 Supplement 3 p. 4728-4734
7 p.
artikel
109 Immunogenicity of hepatitis B vaccine among hemodialysis patients: Effect of revaccination of non-responders and duration of protection Chaves, Sandra S.
2011
29 Supplement 3 p. 9618-9623
6 p.
artikel
110 Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration Cherif, Mahamoud Sama
2011
29 Supplement 3 p. 9038-9050
13 p.
artikel
111 Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation Dolter, Karen E.
2011
29 Supplement 3 p. 795-803
9 p.
artikel
112 Impact of birth weight at term on rates of emergency room visits and hospital admissions following vaccination at 2 months of age Wilson, Kumanan
2011
29 Supplement 3 p. 8267-8274
8 p.
artikel
113 Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges Hanquet, Germaine
2011
29 Supplement 3 p. 2856-2864
9 p.
artikel
114 Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age Hendrikx, Lotte H.
2011
29 Supplement 3 p. 5725-5730
6 p.
artikel
115 Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage Prymula, Roman
2011
29 Supplement 3 p. 1959-1967
9 p.
artikel
116 Implementation and evaluation of the Reaching Every District (RED) strategy in Assam, India, 2005–2008 Ryman, Tove K.
2011
29 Supplement 3 p. 2555-2560
6 p.
artikel
117 Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice Wu, Juan
2011
29 Supplement 3 p. 7624-7630
7 p.
artikel
118 Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response Moraes, Mauro Pires
2011
29 Supplement 3 p. 9431-9440
10 p.
artikel
119 In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: Multifaceted biochemical and immunochemical characterization Zhao, Qinjian
2011
29 Supplement 3 p. 7936-7941
6 p.
artikel
120 Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI) Taylor, David N.
2011
29 Supplement 3 p. 4897-4902
6 p.
artikel
121 Influenza A (H1N1) 2009 two-dose immunization of US children: An observer-blinded, randomized, placebo-controlled trial Plennevaux, Eric
2011
29 Supplement 3 p. 1569-1575
7 p.
artikel
122 Influenza vaccine coverage, influenza-associated morbidity and all-cause mortality in Catalonia (Spain) Muñoz, M. Pilar
2011
29 Supplement 3 p. 5047-5052
6 p.
artikel
123 Influenza vaccine effectiveness in Wisconsin during the 2007–08 season: Comparison of interim and final results Belongia, Edward A.
2011
29 Supplement 3 p. 6558-6563
6 p.
artikel
124 Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice Madhun, Abdullah S.
2011
29 Supplement 3 p. 4973-4982
10 p.
artikel
125 Intranasal co-administration with the mouse zona pellucida 3 expressing construct and its coding protein induces contraception in mice Zhang, Ailian
2011
29 Supplement 3 p. 6785-6792
8 p.
artikel
126 Invasive pneumococcal disease: Association between serotype, clinical presentation and lethality Rodríguez, Mª Angeles Gutiérrez
2011
29 Supplement 3 p. 5740-5746
7 p.
artikel
127 Invasive pneumococcal disease in Catalonian elderly people, 2002–2009: Serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era Vila-Corcoles, Angel
2011
29 Supplement 3 p. 7430-7434
5 p.
artikel
128 Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination Parretta, Elisabetta
2011
29 Supplement 3 p. 3708-3713
6 p.
artikel
129 Kinetics of maternal antibodies against rubella and varicella in infants Leuridan, E.
2011
29 Supplement 3 p. 2222-2226
5 p.
artikel
130 Malaria vaccine candidate: Design of a multivalent subunit α-helical coiled coil poly-epitope Olugbile, Sope
2011
29 Supplement 3 p. 7090-7099
10 p.
artikel
131 Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers Rynkiewicz, Dianna
2011
29 Supplement 3 p. 6313-6320
8 p.
artikel
132 Maternal antibodies to rotavirus: Could they interfere with live rotavirus vaccines in developing countries? Chan, J.
2011
29 Supplement 3 p. 1242-1247
6 p.
artikel
133 Measles susceptibility in children in Karachi, Pakistan Sheikh, Sana
2011
29 Supplement 3 p. 3419-3423
5 p.
artikel
134 Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US Shea, K.M.
2011
29 Supplement 3 p. 8042-8048
7 p.
artikel
135 Mother–infant vaccination with pneumococcal polysaccharide vaccine: Persistence of maternal antibodies and responses of infants to vaccination Holmlund, Emma
2011
29 Supplement 3 p. 4565-4575
11 p.
artikel
136 Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1–43/IL-10 cDNA Hara, Hideo
2011
29 Supplement 3 p. 7474-7482
9 p.
artikel
137 MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8+ T lymphocytes Mendes, Érica A.
2011
29 Supplement 3 p. 4476-4484
9 p.
artikel
138 Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx Kodama, Satoru
2011
29 Supplement 3 p. 1881-1890
10 p.
artikel
139 “Once I begin to participate, people will run away from me”: Understanding stigma as a barrier to HIV vaccine research participation in Kenya Nyblade, Laura
2011
29 Supplement 3 p. 8924-8928
5 p.
artikel
140 Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age Russell, F.M.
2011
29 Supplement 3 p. 535-544
10 p.
artikel
141 Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans Wu, Jiang
2011
29 Supplement 3 p. 1009-1016
8 p.
artikel
142 Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate Asensio, Cristian J.A.
2011
29 Supplement 3 p. 1649-1656
8 p.
artikel
143 Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004–2009 Williams, S. Elizabeth
2011
29 Supplement 3 p. 6920-6927
8 p.
artikel
144 Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: Immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination Lagler, Heimo
2011
29 Supplement 3 p. 6888-6893
6 p.
artikel
145 Pandemic influenza H1N1 2009 infection in Victoria, Australia: No evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009 Kelly, Heath A.
2011
29 Supplement 3 p. 6419-6426
8 p.
artikel
146 Partial protection against classical swine fever virus elicited by dendrimeric vaccine-candidate peptides in domestic pigs Tarradas, Joan
2011
29 Supplement 3 p. 4422-4429
8 p.
artikel
147 Patterns of emergency room visits, admissions and death following recommended pediatric vaccinations—A population based study of 969,519 vaccination events Wilson, Kumanan
2011
29 Supplement 3 p. 3746-3752
7 p.
artikel
148 Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine Weston, Wayde
2011
29 Supplement 3 p. 8483-8486
4 p.
artikel
149 Pertussis after end of a mass vaccination project—End of the “vaccination honey-moon” Trollfors, Birger
2011
29 Supplement 3 p. 2444-2450
7 p.
artikel
150 Pharmacology and toxicology of an oral tablet whole cells inactivated cholera vaccine in Sprague Dawley rats López, Yulieé
2011
29 Supplement 3 p. 3596-3599
4 p.
artikel
151 Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine Gadzinowski, Janusz
2011
29 Supplement 3 p. 2947-2955
9 p.
artikel
152 Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance van den Biggelaar, Anita H.J.
2011
29 Supplement 3 p. 5414-5420
7 p.
artikel
153 Pneumococcal disease manifestation in children before and after vaccination: What's new? Andrade, Ana Lucia
2011
29 Supplement 3 p. C2-C14
nvt p.
artikel
154 Polyfunctional analysis of Gag and Nef specific CD8+ T-cell responses in HIV-1 infected Indian individuals Mendiratta, Sanjay
2011
29 Supplement 3 p. 1150-1158
9 p.
artikel
155 Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model Skinner, Julie M.
2011
29 Supplement 3 p. 8870-8876
7 p.
artikel
156 Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes Niu, Liguo
2011
29 Supplement 3 p. 2110-2119
10 p.
artikel
157 Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States Wang, Xin
2011
29 Supplement 3 p. 4739-4744
6 p.
artikel
158 Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy Lao-araya, Mongkol
2011
29 Supplement 3 p. 3977-3981
5 p.
artikel
159 Prevenar experience Arguedas, Adriano
2011
29 Supplement 3 p. C26-C34
nvt p.
artikel
160 Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies Canfell, Karen
2011
29 Supplement 3 p. 2487-2494
8 p.
artikel
161 Prevention of pneumococcal disease through vaccination Gentile, Angela
2011
29 Supplement 3 p. C15-C25
nvt p.
artikel
162 Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling Partidos, Charalambos D.
2011
29 Supplement 3 p. 3067-3073
7 p.
artikel
163 Productive infection of human hepatocellular carcinoma cells by porcine circovirus type 1 Beach, Nathan M.
2011
29 Supplement 3 p. 7303-7306
4 p.
artikel
164 Promoter control over foreign antigen expression in a murine cytomegalovirus vaccine vector Cunningham, Paula T.
2010
29 Supplement 3 p. 141-151
11 p.
artikel
165 Prospective pertussis surveillance in Switzerland, 1991–2006 Wymann, Monica N.
2011
29 Supplement 3 p. 2058-2065
8 p.
artikel
166 Protection from persistent infection with a bovine viral diarrhea virus (BVDV) type 1b strain by a modified-live vaccine containing BVDV types 1a and 2, infectious bovine rhinotracheitis virus, parainfluenza 3 virus and bovine respiratory syncytial virus Xue, Wenzhi
2011
29 Supplement 3 p. 4657-4662
6 p.
artikel
167 Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate Windish, Hillarie Plessner
2011
29 Supplement 3 p. 7842-7848
7 p.
artikel
168 Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine Ashraf, Shamaila
2011
29 Supplement 3 p. 3990-4002
13 p.
artikel
169 Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression Bunupuradah, Torsak
2011
29 Supplement 3 p. 2962-2967
6 p.
artikel
170 Rapid, non-invasive imaging of alphaviral brain infection: Reducing animal numbers and morbidity to identify efficacy of potential vaccines and antivirals Patterson, Michael
2011
29 Supplement 3 p. 9345-9351
7 p.
artikel
171 Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults Leeb, Alan
2011
29 Supplement 3 p. 7920-7924
5 p.
artikel
172 Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4–6 years old Quinn, Patrick
2011
29 Supplement 3 p. 4230-4237
8 p.
artikel
173 Recurrent apnoea post immunisation: Informing re-immunisation policy Clifford, Vanessa
2011
29 Supplement 3 p. 5681-5687
7 p.
artikel
174 Regional patterns of mortality during the 1918 influenza pandemic in Newfoundland Sattenspiel, Lisa
2011
29 Supplement 3 p. B33-B37
nvt p.
artikel
175 Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17–18 February 2011 Girard, Marc P.
2011
29 Supplement 3 p. 7579-7586
8 p.
artikel
176 Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response DiNapoli, Joshua M.
2010
29 Supplement 3 p. 17-25
9 p.
artikel
177 Response of MUTZ-3 dendritic cells to the different components of the Haemophilus influenzae type B conjugate vaccine: Towards an in vitro assay for vaccine immunogenicity Hoefnagel, Marcel H.N.
2011
29 Supplement 3 p. 5114-5121
8 p.
artikel
178 Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: A database study Stowe, Julia
2011
29 Supplement 3 p. 9467-9472
6 p.
artikel
179 Safety and immunogenicity of a candidate parvovirus B19 vaccine Bernstein, David I.
2011
29 Supplement 3 p. 7357-7363
7 p.
artikel
180 Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02) García, Felipe
2011
29 Supplement 3 p. 8309-8316
8 p.
artikel
181 Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults Turley, Christine B.
2011
29 Supplement 3 p. 5145-5152
8 p.
artikel
182 Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 4, 6 and 12–14 months of age Diaz-Mitoma, Francisco
2011
29 Supplement 3 p. 1324-1331
8 p.
artikel
183 Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis Wang, Ling-yun
2011
29 Supplement 3 p. 2679-2681
3 p.
artikel
184 Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh Rahman, Kazi Mizanur
2011
29 Supplement 3 p. 1347-1354
8 p.
artikel
185 Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid protein of feline infectious peritonitis virus Satoh, Ryoichi
2011
29 Supplement 3 p. 1791-1800
10 p.
artikel
186 Seasonal influenza vaccination in adults: Practice and attitudes about collaborative delivery with community vaccinators Hurley, Laura P.
2011
29 Supplement 3 p. 8649-8655
7 p.
artikel
187 Seroprevalence of varicella zoster virus among pregnant women in Hong Kong: Comparison with self-reported history Fung, Linda Wen Ying
2011
29 Supplement 3 p. 8186-8188
3 p.
artikel
188 Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae prior to introduction of the 10-valent pneumococcal conjugate vaccine in Brazil, 2000–2007 Menezes, Ana Paula de O.
2011
29 Supplement 3 p. 1139-1144
6 p.
artikel
189 Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months Russell, F.M.
2011
29 Supplement 3 p. 4499-4506
8 p.
artikel
190 Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease Yildirim, Inci
2010
29 Supplement 3 p. 283-288
6 p.
artikel
191 SLAM and DC-SIGN measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine Clifford, Holly D.
2011
29 Supplement 3 p. 5407-5413
7 p.
artikel
192 Smallpox eradication in Bangladesh, 1972–1976 Foster, Stanley O.
2011
29 Supplement 3 p. D22-D29
nvt p.
artikel
193 Stability of RNA virus attenuation approaches Kenney, Joan L.
2011
29 Supplement 3 p. 2230-2234
5 p.
artikel
194 Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: Lessons learned by PAHO's ProVac Initiative Jauregui, Barbara
2011
29 Supplement 3 p. 1099-1106
8 p.
artikel
195 Streptococcus pneumoniae serotypes in Utah adults at the end of the PCV7 era Kendall, Brian A.
2011
29 Supplement 3 p. 9123-9126
4 p.
artikel
196 Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice Amuguni, J. Hellen
2011
29 Supplement 3 p. 4778-4784
7 p.
artikel
197 Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine Zhang, Wei
2011
29 Supplement 3 p. 6276-6282
7 p.
artikel
198 T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep Rojas, José-Manuel
2011
29 Supplement 3 p. 6848-6857
10 p.
artikel
199 Temporal development of the humoral immune response to surface antigens of Moraxella catarrhalis in young infants Verhaegh, Suzanne J.C.
2011
29 Supplement 3 p. 5603-5610
8 p.
artikel
200 Ten years of Hib vaccination in Italy: Prevalence of non-encapsulated Haemophilus influenzae among invasive isolates and the possible impact on antibiotic resistance Giufrè, Maria
2011
29 Supplement 3 p. 3857-3862
6 p.
artikel
201 The current status of invasive pneumococcal disease in Poland Skoczyńska, Anna
2011
29 Supplement 3 p. 2199-2205
7 p.
artikel
202 The factor H-binding fragment of PspC as a vaccine antigen for the induction of protective humoral immunity against experimental pneumococcal sepsis Ricci, Susanna
2011
29 Supplement 3 p. 8241-8249
9 p.
artikel
203 The future of pneumococcal disease prevention Rodgers, Gail L.
2011
29 Supplement 3 p. C43-C48
nvt p.
artikel
204 The global polio eradication initiative: Lessons learned and prospects for success Aylward, Bruce
2011
29 Supplement 3 p. D80-D85
nvt p.
artikel
205 The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children Thanee, Chareeya
2011
29 Supplement 3 p. 5886-5891
6 p.
artikel
206 The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children Okike, Ifeanyichukwu O.
2011
29 Supplement 3 p. 6636-6640
5 p.
artikel
207 The immunogenicity of pneumococcal polysaccharides in infants and children: A meta-regression Laferriere, Craig
2011
29 Supplement 3 p. 6838-6847
10 p.
artikel
208 The 1918 influenza pandemic in Florianopolis: A subtropical city in Brazil Alonso, Wladimir J.
2011
29 Supplement 3 p. B16-B20
nvt p.
artikel
209 The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response Seyoum, Beza
2011
29 Supplement 3 p. 8002-8011
10 p.
artikel
210 The optimal number of routine vaccines to order at health clinics in low or middle income countries Rajgopal, Jayant
2011
29 Supplement 3 p. 5512-5518
7 p.
artikel
211 The PEDVAC trial: Preliminary data from the first therapeutic DNA vaccination in HIV-infected children Palma, Paolo
2011
29 Supplement 3 p. 6810-6816
7 p.
artikel
212 The perils of using annual all-cause mortality data to estimate pandemic influenza burden Andreasen, Viggo
2011
29 Supplement 3 p. B49-B55
nvt p.
artikel
213 The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia Smith, Megan A.
2011
29 Supplement 3 p. 9112-9122
11 p.
artikel
214 Therapeutic cancer vaccines: Why so few randomised phase III studies reflect the initial optimism of phase II studies Dalgleish, Angus G.
2011
29 Supplement 3 p. 8501-8505
5 p.
artikel
215 The recombinant gut-associated M17 leucine aminopeptidase in combination with different adjuvants confers a high level of protection against Fasciola hepatica infection in sheep Maggioli, Gabriela
2011
29 Supplement 3 p. 9057-9063
7 p.
artikel
216 Transmission of mumps virus from mumps-vaccinated individuals to close contacts Fanoy, Ewout B.
2011
29 Supplement 3 p. 9551-9556
6 p.
artikel
217 Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model Kollessery, Gayathri
2011
29 Supplement 3 p. 5904-5910
7 p.
artikel
218 Universal screening for hepatitis B among pregnant women led to 96% vaccination coverage among newborns of HBsAg positive mothers in Denmark Harder, Katja Majlund
2011
29 Supplement 3 p. 9303-9307
5 p.
artikel
219 Updated aluminum pharmacokinetics following infant exposures through diet and vaccination Mitkus, Robert J.
2011
29 Supplement 3 p. 9538-9543
6 p.
artikel
220 Vaccination status and sequence of vaccinations as risk factors for hospitalisation among outpatients in a high mortality country Biai, Sidu
2011
29 Supplement 3 p. 3662-3669
8 p.
artikel
221 Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus Loeffen, W.L.A.
2011
29 Supplement 3 p. 1545-1550
6 p.
artikel
222 Validity and reliability of a survey to identify vaccine-hesitant parents Opel, Douglas J.
2011
29 Supplement 3 p. 6598-6605
8 p.
artikel
223 Viral interference induced by live attenuated virus vaccine (OPV) can prevent otitis media Seppälä, Elina
2011
29 Supplement 3 p. 8615-8618
4 p.
artikel
224 Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice Chauhan, Neelima B.
2011
29 Supplement 3 p. 7631-7637
7 p.
artikel
225 Worsening disparities in HPV vaccine utilization among 19–26 year old women Dempsey, Amanda
2011
29 Supplement 3 p. 528-534
7 p.
artikel
                             225 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland